RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Ocumension, a Hong Kong ophthalmology company, acquired greater China rights to a treatment for acute blepharitis from France’s Nicox in a $13.5 million agreement. Blepharitis is characterized by inflammation of the eyelid. NCX 4251, the third product that Ocumension has in-licensed from Nicox, is currently in a US Phase II trial. Previously, Ocumension acquired China rights to NCX 470 for glaucoma and ZerviateTM for allergic conjunctivitis. Ocumension is wholly owned by 6 Dimensions Capital, an investment firm formed by the merger of Wuxi Healthcare Ventures and Frontline BioVentures.
Source: China Biotoday
